Company intelligence / Profile preview

Kalaco Scientific

Scottsdale, Arizona, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

Kalaco Scientific developed the Nexalin electrostimulation medical device intended for transcranial electronic stimulation to treat symptoms of depression and possibly other neuropsychiatric conditions. A Phase II clinical trial was conducted to assess safety and efficacy in mild-to-moderate depression; results are not publicly detailed beyond completion status. The company has also been associated with citalopram hydrobromide in its pipeline database entries, but this is likely due to involvement in related trials rather than drug development itself.

Therapeutic areas: Psychiatry
Modalities: DeviceElectrotherapy device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Kalaco Scientific.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kalaco Scientific.

Explore the full profile